Efficacy and Safety of Pegzilarginase in Arginase 1 Deficiency (PEACE): a Phase 3, Randomized, Double-blind, Placebo-controlled, Multi-centre Trial

Overview

Journal EClinicalMedicine

Specialty General Medicine

Date 2024 Jan 31

PMID 38292042

Authors

Rossana Sanchez Russo

Serena Gasperini

Gillian Bubb

Linda Neuman

Leslie S Sloan

George A Diaz

Gregory M Enns

Affiliations

Soon will be listed here.

Abstract

Background: Arginase 1 Deficiency (ARG1-D) is a rare debilitating, progressive, inherited, metabolic disease characterized by marked increases in plasma arginine (pArg) and its metabolites, with increased morbidity, substantial reductions in quality of life, and premature mortality. Effective treatments that can lower arginine and improve clinical outcomes is currently lacking. Pegzilarginase is a novel human arginase 1 enzyme therapy. The present trial aimed to demonstrate efficacy of pegzilarginase on pArg and key mobility outcomes.

Methods: This Phase 3 randomized, double-blind, placebo-controlled, parallel-group clinical trial (clinicaltrials.govNCT03921541, EudraCT 2018-004837-34), randomized patients with ARG1-D 2:1 to intravenously/subcutaneously once-weekly pegzilarginase or placebo in conjunction with their individualized disease management. It was conducted in 7 countries; United States, United Kingdom, Canada, Austria, France, Germany, Italy. Primary endpoint was change from baseline in pArg after 24 weeks; key secondary endpoints were change from baseline at Week 24 in Gross Motor Function Measure part E (GMFM-E) and 2-min walk test (2MWT). Full Analysis Set was used for the analyses.

Findings: From 01 May 2019 to 29 March 2021, 32 patients were enrolled and randomized (pegzilarginase, n = 21; placebo, n = 11). Pegzilarginase lowered geometric mean pArg from 354.0 μmol/L to 86.4 μmol/L at Week 24 vs 464.7 to 426.6 μmol/L for placebo (95% CI: -67.1%, -83.5%; < 0.0001) and normalized levels in 90.5% of patients (vs 0% with placebo). In addition, clinically relevant functional mobility improvements were demonstrated with pegzilarginase treatment. These effects were sustained long-term through additional 24 weeks of subsequent exposure. Pegzilarginase was well-tolerated, with adverse events being mostly transient and mild/moderate in severity.

Interpretation: These results support pegzilarginase as the first potential treatment to normalize pArg in ARG1-D and achieve clinically meaningful improvements in functional mobility.

Funding: Aeglea BioTherapeutics.

Citing Articles

Disease burden among patients with Arginase 1 deficiency and their caregivers: A multinational, cross-sectional survey.

Olofsson S, Lofvendahl S, Widen J, Jacobson L, Lindgren P, Stepien K JIMD Rep. 2024; 65(6):450-460.

PMID: 39512431 PMC: 11540579. DOI: 10.1002/jmd2.12456.

Retrospective analysis of arginase 1 deficiency progression in adults over 5 years at a single metabolic centre.

Sharma R, Bassett J, Stepien K, Oldham A, Jovanovic A, Woodall A JIMD Rep. 2024; 65(6):382-391.

PMID: 39512428 PMC: 11540583. DOI: 10.1002/jmd2.12450.

Microglia LILRB4 upregulation reduces brain damage after acute ischemic stroke by limiting CD8 T cell recruitment.

Ma Y, Zheng K, Zhao C, Chen J, Chen L, Zhang Y J Neuroinflammation. 2024; 21(1):214.

PMID: 39217343 PMC: 11366150. DOI: 10.1186/s12974-024-03206-4.

References

Oeffinger D, Bagley A, Rogers S, Gorton G, Kryscio R, Abel M . Outcome tools used for ambulatory children with cerebral palsy: responsiveness and minimum clinically important differences. Dev Med Child Neurol. 2008; 50(12):918-25. PMC: 2990955. DOI: 10.1111/j.1469-8749.2008.03150.x. View

Schlune A, Vom Dahl S, Haussinger D, Ensenauer R, Mayatepek E . Hyperargininemia due to arginase I deficiency: the original patients and their natural history, and a review of the literature. Amino Acids. 2015; 47(9):1751-62. DOI: 10.1007/s00726-015-2032-z. View

Catsburg C, Anderson S, Upadhyaya N, Bechter M . Arginase 1 Deficiency: using genetic databases as a tool to establish global prevalence. Orphanet J Rare Dis. 2022; 17(1):94. PMC: 8889696. DOI: 10.1186/s13023-022-02226-8. View

Stone E, Chantranupong L, Gonzalez C, ONeal J, Rani M, VanDenBerg C . Strategies for optimizing the serum persistence of engineered human arginase I for cancer therapy. J Control Release. 2011; 158(1):171-9. PMC: 3294146. DOI: 10.1016/j.jconrel.2011.09.097. View

Amayreh W, Meyer U, Das A . Treatment of arginase deficiency revisited: guanidinoacetate as a therapeutic target and biomarker for therapeutic monitoring. Dev Med Child Neurol. 2014; 56(10):1021-4. DOI: 10.1111/dmcn.12488. View

Deignan J, Marescau B, Livesay J, Iyer R, De Deyn P, Cederbaum S . Increased plasma and tissue guanidino compounds in a mouse model of hyperargininemia. Mol Genet Metab. 2007; 93(2):172-8. DOI: 10.1016/j.ymgme.2007.09.016. View

Marescau B, De Deyn P, Qureshi I, De Broe M, Antonozzi I, Cederbaum S . The pathobiochemistry of uremia and hyperargininemia further demonstrates a metabolic relationship between urea and guanidinosuccinic acid. Metabolism. 1992; 41(9):1021-4. DOI: 10.1016/0026-0495(92)90131-s. View

Broer A, Wagner C, Lang F, Broer S . The heterodimeric amino acid transporter 4F2hc/y+LAT2 mediates arginine efflux in exchange with glutamine. Biochem J. 2000; 349 Pt 3:787-95. PMC: 1221206. DOI: 10.1042/bj3490787. View

Carvalho D, Brum J, Speck-Martins C, Ventura F, Navarro M, Coelho K . Clinical features and neurologic progression of hyperargininemia. Pediatr Neurol. 2012; 46(6):369-74. DOI: 10.1016/j.pediatrneurol.2012.03.016. View

10.

White M . The transport of cationic amino acids across the plasma membrane of mammalian cells. Biochim Biophys Acta. 1985; 822(3-4):355-74. DOI: 10.1016/0304-4157(85)90015-2. View

11.

Stone E, Glazer E, Chantranupong L, Cherukuri P, Breece R, Tierney D . Replacing Mn(2+) with Co(2+) in human arginase i enhances cytotoxicity toward l-arginine auxotrophic cancer cell lines. ACS Chem Biol. 2010; 5(3):333-42. PMC: 2842482. DOI: 10.1021/cb900267j. View

12.

Morris Jr S . Arginine Metabolism Revisited. J Nutr. 2016; 146(12):2579S-2586S. DOI: 10.3945/jn.115.226621. View

13.

Bin Sawad A, Pothukuchy A, Badeaux M, Hodson V, Bubb G, Lindsley K . Natural history of arginase 1 deficiency and the unmet needs of patients: A systematic review of case reports. JIMD Rep. 2022; 63(4):330-340. PMC: 9259395. DOI: 10.1002/jmd2.12283. View

14.

Closs E, Simon A, Vekony N, Rotmann A . Plasma membrane transporters for arginine. J Nutr. 2004; 134(10 Suppl):2752S-2759S. DOI: 10.1093/jn/134.10.2752S. View

15.

Cederbaum S, SHAW K, Valente M . Hyperargininemia. J Pediatr. 1977; 90(4):569-73. DOI: 10.1016/s0022-3476(77)80368-5. View

16.

Luneburg N, Xanthakis V, Schwedhelm E, Sullivan L, Maas R, Anderssohn M . Reference intervals for plasma L-arginine and the L-arginine:asymmetric dimethylarginine ratio in the Framingham Offspring Cohort. J Nutr. 2011; 141(12):2186-90. PMC: 3223876. DOI: 10.3945/jn.111.148197. View

17.

Deignan J, De Deyn P, Cederbaum S, Fuchshuber A, Roth B, Gsell W . Guanidino compound levels in blood, cerebrospinal fluid, and post-mortem brain material of patients with argininemia. Mol Genet Metab. 2010; 100 Suppl 1:S31-6. DOI: 10.1016/j.ymgme.2010.01.012. View

18.

Wu G, Bazer F, Davis T, Kim S, Li P, Rhoads J . Arginine metabolism and nutrition in growth, health and disease. Amino Acids. 2008; 37(1):153-68. PMC: 2677116. DOI: 10.1007/s00726-008-0210-y. View

19.

De Deyn P, Marescau B, Macdonald R . Guanidino compounds that are increased in hyperargininemia inhibit GABA and glycine responses on mouse neurons in cell culture. Epilepsy Res. 1991; 8(2):134-41. DOI: 10.1016/0920-1211(91)90081-p. View

20.

Diaz G, Schulze A, McNutt M, Leao-Teles E, Merritt 2nd J, Enns G . Clinical effect and safety profile of pegzilarginase in patients with arginase 1 deficiency. J Inherit Metab Dis. 2020; 44(4):847-856. PMC: 8359196. DOI: 10.1002/jimd.12343. View